TY - JOUR
T1 - Antibody evolution to SARS-CoV-2 after single-dose Ad26.COV2.S vaccine in humans
AU - Cho, Alice
AU - Muecksch, Frauke
AU - Wang, Zijun
AU - Tanfous, Tarek Ben
AU - Dasilva, Justin
AU - Raspe, Raphael
AU - Johnson, Brianna
AU - Bednarski, Eva
AU - Ramos, Victor
AU - Schaefer-Babajew, Dennis
AU - Shimeliovich, Irina
AU - Dizon, Juan P.
AU - Yao, Kai Hui
AU - Schmidt, Fabian
AU - Millard, Katrina G.
AU - Turroja, Martina
AU - Jankovic, Mila
AU - Oliveira, Thiago Y.
AU - Gazumyan, Anna
AU - Gaebler, Christian
AU - Caskey, Marina
AU - Hatziioannou, Theodora
AU - Bieniasz, Paul D.
AU - Nussenzweig, Michel C.
N1 - Generated from Scopus record by KAUST IRTS on 2023-02-15
PY - 2022/8/1
Y1 - 2022/8/1
N2 - The single-dose Ad.26.COV.2 (Janssen) vaccine elicits lower levels of neutralizing antibodies and shows more limited efficacy in protection against infection than either of the two available mRNA vaccines. In addition, Ad.26.COV.2 has been less effective in protection against severe disease during the Omicron surge. Here, we examined the memory B cell response to single-dose Ad.26.COV.2 vaccination. Compared with mRNA vaccines, Ad.26.COV.2 recipients had significantly lower numbers of RBDspecific memory B cells 1.5 or 6 mo after vaccination. Despite the lower numbers, the overall quality of the memory B cell responses appears to be similar, such that memory antibodies elicited by both vaccine types show comparable neutralizing potency against SARS-CoV-2 Wuhan-Hu-1, Delta, and Omicron BA.1 variants. The data help explain why boosting Ad.26.COV.2 vaccine recipients with mRNA vaccines is effective and why the Ad26.COV2.S vaccine can maintain some protective efficacy against severe disease during the Omicron surge.
AB - The single-dose Ad.26.COV.2 (Janssen) vaccine elicits lower levels of neutralizing antibodies and shows more limited efficacy in protection against infection than either of the two available mRNA vaccines. In addition, Ad.26.COV.2 has been less effective in protection against severe disease during the Omicron surge. Here, we examined the memory B cell response to single-dose Ad.26.COV.2 vaccination. Compared with mRNA vaccines, Ad.26.COV.2 recipients had significantly lower numbers of RBDspecific memory B cells 1.5 or 6 mo after vaccination. Despite the lower numbers, the overall quality of the memory B cell responses appears to be similar, such that memory antibodies elicited by both vaccine types show comparable neutralizing potency against SARS-CoV-2 Wuhan-Hu-1, Delta, and Omicron BA.1 variants. The data help explain why boosting Ad.26.COV.2 vaccine recipients with mRNA vaccines is effective and why the Ad26.COV2.S vaccine can maintain some protective efficacy against severe disease during the Omicron surge.
UR - https://rupress.org/jem/article/219/8/e20220732/213320/Antibody-evolution-to-SARS-CoV-2-after-single-dose
UR - http://www.scopus.com/inward/record.url?scp=85134083247&partnerID=8YFLogxK
U2 - 10.1084/jem.20220732
DO - 10.1084/jem.20220732
M3 - Article
C2 - 35776090
SN - 0022-1007
VL - 219
JO - Journal of Experimental Medicine
JF - Journal of Experimental Medicine
IS - 8
ER -
